The Neuropeptide α-Calcitonin Gene-Related Peptide as the Mediator of Beneficial Effects of Exercise in the Cardiovascular System

Tom Skaria¹ and Johannes Vogel²*

¹ School of Biotechnology, National Institute of Technology Calicut, Kerala, India, ² Zürich Center for Integrative Human Physiology, Institute of Veterinary Physiology, University of Zurich, Zurich, Switzerland

Regular physical activity exerts cardiovascular protective effects in healthy individuals and those with chronic cardiovascular diseases. Exercise is accompanied by an increased plasma concentration of α-calcitonin gene-related peptide (αCGRP), a 37-amino acid peptide with vasodilatory effects and causative roles in migraine. Moreover, mouse models revealed that loss of αCGRP disrupts physiological adaptation of the cardiovascular system to exercise in normotension and aggravates cardiovascular impairment in primary chronic hypertension, both can be reversed by αCGRP administration. This suggests that αCGRP agonists could be a therapeutic option to mediate the cardiovascular protective effects of exercise in clinical setting where exercise is not possible or contraindicated. Of note, FDA has recently approved αCGRP antagonists for migraine prophylaxis therapy, however, the cardiovascular safety of long-term anti-CGRP therapy in individuals with cardiovascular diseases has yet to be established. Current evidence from preclinical models suggests that chronic αCGRP antagonism may abolish the cardiovascular protective effects of exercise in both normotension and chronic hypertension.

Keywords: exercise, cardiovascular health, αCGRP, myokines, migraine

INTRODUCTION

Cardiovascular diseases (CVD) including hypertensive heart disease, heart failure (HF), peripheral arterial disease, and stroke represent the main cause of morbidity and mortality. During the past decades, the number of deaths due to CVD increased steadily and it is estimated that CVD may cause more than 230 million deaths across the globe in 2030. Moreover, more than 10% of world’s annual total healthcare expenditure is spent for CVD (Roth et al., 2020; Amini et al., 2021).

Cardiovascular diseases is attributed to factors such as hypertension, unhealthy diet, heavy alcohol drinking, overweight, diabetes mellitus and physical inactivity (Amini et al., 2021). Numerous studies reveal that physical activity (PA) or reversal of sedentary lifestyle reduces the risk of cardiovascular events including HF and stroke (Virani et al., 2021). PA or exercise not only reduces the risk of CVD in healthy subjects but is also a central part of cardiac rehabilitation program recommended for subjects with CVD to reduce secondary events, hospital admissions and mortality (Virani et al., 2021). In fact, the ability of regular PA to increase cardiorespiratory fitness (CRF), an indicator of metabolic health, and thus to decrease CVD is well demonstrated (Kodama et al., 2009).
Additionally, regular PA lowers the incidence of typical CVD risk factors such as systemic hypertension, hyperlipidemia, and diabetes mellitus. It also exerts direct beneficial effects on the structure of blood vessels and myocardium, improves autonomic balance and attenuates tissue damaging chronic proinflammatory responses (Fiuza-Luces et al., 2018). Thus, there is no doubt that exercise is beneficial in reducing CVD risk in healthy subjects and improving cardiovascular function in cardiovascular-compromised patients.

α-CALCITONIN GENE-RELATED PEPTIDE: A DRUGGABLE MOLECULAR MEDIATOR OF CARDIOVASCULAR PROTECTIVE EFFECTS OF EXERCISE

Myokines, the peptides secreted by exercising skeletal muscles or nerve fibers innervating the contracting muscles, play important roles in mediating some of the structural and functional cardiovascular benefits of exercise (Pinckard et al., 2019). Myokines with prominent effects on cardiovascular system include C1q/TNF-related protein-1, neuron-derived neurotrophic factor, follistatin-like 1, IL-6 (Pinckard et al., 2019) and α-Calcitonin Gene-Related Peptide (αCGRP). Whether C1q/TNF-related protein-1, neuron-derived neurotrophic factor, follistatin-like 1 and IL-6 are indispensable for cardiovascular protective effects of exercise, i.e., whether their deficiency adversely affect the cardiovascular system during exercise, and their druggability still need to be defined by preclinical studies. αCGRP is a 37-amino acid druggable peptide released by nerve fibers of exercising skeletal muscles, trigeminal and perivascular nerves, endothelium, adipocytes, activated B lymphocytes, macrophages and keratinocytes. It differs from its isoform βCGRP by only three amino acids in humans. Sensory neurons preferentially express αCGRP (3–6 times higher than βCGRP) while in enteric neurons, βCGRP is up to 7 times more abundant than αCGRP [extensively reviewed by Russell et al. (2014) and Mulderry et al. (1988)]. αCGRP interacts with the receptor formed of calcitonin receptor-like receptor (CLR), receptor activity modifying protein (RAMP) and receptor component protein. Association of RAMP1 with CLR forms the specific receptor for CGRP whereas that of RAMP2 with CLR constitute the receptor for adrenomedullin [extensively discussed by Russell et al. (2014) and Liang et al. (2018)]. αCGRP, recently shown to mediate physiological cardiovascular adaptations to exercise in normotension and cardiovascular protective effects of exercise in chronic hypertension in preclinical models, is the focus of this review.

Plasma and Muscle Tissue Concentrations of α-Calcitonin Gene-Related Peptide Increase During Exercise

A previous study observed highly increased plasma αCGRP concentrations in response to exercise in human runners before a training break, following 3 weeks of physical inactivity, and 2 and 4 weeks after recommencement of training, which showed positive correlation with heart rate (Schifter et al., 1995). Others found progressive increase in plasma αCGRP concentration during exercise in normal humans, hypertensives and diabetes patients and highest αCGRP concentration was observed at maximum exercise (Lind et al., 1996). A recent study has shown increased circulating αCGRP concentration in response to maximal exercise in 2/3 of study subjects who were healthy adults (Aracil-Marco et al., 2021). In another study on subjects suffering from headache and headache-free subjects, endurance exercise increased plasma αCGRP concentration, and the post-run variation of circulating αCGRP was inversely related to running time (Tarperi et al., 2020). Moreover, graded exercise was shown to increase plasma αCGRP concentration in normal healthy subjects and those with coronary heart disease (CHD) with an additional, interesting finding that lower workload results in highest αCGRP concentrations in subjects with CHD. Increased oxygen demand in CHD might cause an earlier αCGRP release from sensory neurons during exercise (Lechleitner et al., 1994). Another study found increase in circulating αCGRP concentrations in close linear correlation to lactate in response to exercise in healthy sea level natives at sea level and subsequently after 24 h and 5 days in high altitude hypoxia. αCGRP release was not associated with increase in catecholamines or sympathetic vasoconstrictors like noradrenaline, rather it was strongly correlated with increased lactate levels only (Hasbak et al., 2002).

The major fraction of circulating immunoreactive αCGRP comprises the intact neuropeptide, suggesting exercise-induced αCGRP production and excluding the possibility that the increase in concentrations of immunoreactive αCGRP detected during exercise is caused by molecule degradation products (Schifter, 1991; Schifter et al., 1995; Hasbak et al., 2002). Both endurance and resistance training are capable of increasing αCGRP content in skeletal muscle tissues (Parnow et al., 2012) and increased αCGRP content is detectable in motor neurons and skeletal muscle tissues even 2 days after exercise (Homonko and Theriault, 1997).

Putative Release Mechanism and Source of α-Calcitonin Gene-Related Peptide During Exercise

During exercise, group-III and group-IV afferent neurons containing metaboreceptors and mechanoreceptors within the contracting skeletal muscles are activated. This leads to activation of sympathetic nervous system causing exercise pressor reflex that regulates blood pressure (BP) and heart rate changes during exercise (Cooper et al., 2016). The vanilloid receptor transient receptor potential vanilloid subtype-1 (TRPV1), a ligand-gated non-selective cation channel expressed abundantly in group III afferent neurons, is a metaboreceptor mediating exercise pressor reflex and is activated by capsaicin, noxious heat (43°C), and protons. Lactic acid formation and consequent drop in pH activates TRPV1, leading to both neuronal excocytosis of αCGRP and activation of the nociceptive transcription factor ‘cAMP response element-binding protein’ which in turn enhances αCGRP expression (Figure 1). On the other
Mechanism of \( \alpha \)CGRP release associated with exercise pressor reflex. During exercise, group III and IV afferent neurons within skeletal muscles are activated. This activates the sympathetic nervous system resulting in exercise pressor reflex (lower part of the figure). During exercise, tissue acidification (lactate production and drop in pH) induces \( \alpha \)CGRP release from group III afferents through activation of transient receptor potential vanilloid subtype 1 (TRPV1) channels (dashed arrow, upper part of the figure). Post release, \( \alpha \)CGRP entering the circulation may trigger physiological cardiac hypertrophy in normotension and mediate cardio-protection during pressure overload. ASICs, acid sensing ion channels, HR, heart rate, BP, blood pressure, CO, cardiac output.

Hand, \( \alpha \)CGRP expression is inhibited by an inhibitor of Ca\(^{2+}\)/calmodulin-dependent protein kinase (CaMK), thereby suggesting the involvement of CaMK in the downstream signaling associated with TRPV1-mediated \( \alpha \)CGRP expression (Nakanishi et al., 2010). Lowering the pH or lactic acid alone triggered the release of \( \alpha \)CGRP in rat spinal cord slices, and a combination of lactic acid with low pH, a condition mimicking strenuous exercise, caused more than additive stimulation of \( \alpha \)CGRP release, suggesting lactic acid potentiates low pH-triggered \( \alpha \)CGRP release (Wang and Fiscus, 1997). However, the underlying molecular mechanism involved in lactic acid-potentiated \( \alpha \)CGRP release remain still undefined.

Cardiovascular Protective Effects of Exercise-Activated \( \alpha \)-Calcitonin Gene-Related Peptide Signaling in Physiological States

\( \alpha \)-calcitonin gene-related peptide enhances the synthesis of acetyl choline receptors and activates Na\(^+\)/K\(^+\) pump to counteract exercise-induced K\(^+\) depletion in myocytes. Therefore, an increase in circulating \( \alpha \)CGRP concentrations may enhance both these processes at neuromuscular junctions during exercise (Schiffer et al., 1995). Increase in \( \alpha \)CGRP during exercise may also counteract the vasoconstrictor responses mediated by increased noradrenaline and neuropeptide-Y concentrations during sympathetic activation (Lind et al., 1996). \( \alpha \)CGRP induces vasorelaxation through both endothelium- and NO-dependent and -independent pathways but does not regulate systemic BP in normal individuals (Russell et al., 2014). \( \alpha \)CGRP may activate cAMP-dependent signaling pathways to mediate the cardiovascular protective effects of exercise. \( \alpha \)CGRP protects cardiomyocytes from stress-induced apoptosis (Sueur et al., 2005) and triggers physiological cardiomyocyte growth in vitro, and produces positive inotropy and chronotropy (Bell et al., 1995; Al-Rubaiee et al., 2013; Schuler et al., 2014) which are the main cardiac adaptations to exercise. Exercise training caused fetal gene reactivation in the heart of adult, normotensive \( \alpha \)CGRP knock out mice, resembling the pathological cardiac phenotype typically seen in hypertension. Moreover, treatment with the \( \alpha \)CGRP receptor antagonist CGRP8-37 blunted exercise-induced physiological cardiac hypertrophy in normal mice. Furthermore, exercise performance was attenuated in normotensive, \( \alpha \)CGRP knock out or CGRP8-37-treated wild-type mice but enhanced in transgenic mice overexpressing calcitonin receptor-like receptor (Table 1). This suggests that \( \alpha \)CGRP augments maximum exercise capacity not only by acutely triggering positive chronotropy and inotropy but also by exerting direct hormonal protective effects on the heart to drive physiological cardiac hypertrophy (Schuler et al., 2014).

In accordance with lipolytic effects observed in muscles after CGRP administration (Danaher et al., 2008), an acute increase in plasma \( \alpha \)CGRP concentration enhanced adipose tissue lipolysis during exercise in rats, and this effect was inhibited by pretreatment with CGRP8-37 (Aveseh et al., 2018). This evidence supports the notion that exercise-induced
TABLE 1 | Cardiovascular effects of exercise-activated endogenous, \( \alpha \)CGRP signaling.

| Subjects | Study setting/exercise intervention | Post exercise outcomes/findings on cardiovascular health |
|----------|------------------------------------|-----------------------------------------------------|
| Humans   | Normal, physically active healthy volunteers subjected to a graded exercise test up to exhaustion | Increased plasma \( \alpha \)CGRP concentration accompanied with enhanced cardiorespiratory fitness as indicated by increase in \( \Delta V_{O2} \), \( \Delta V_{CO2} \), carbohydrate oxidation rate and relative power in 2/3 of subjects (Aracil-Marco et al., 2021). |
| Mice     | Adult mice globally deficient for \( \alpha \)CGRP or \( \alpha \)CGRP receptor antagonist-treated WT mice with baseline hemodynamic variables including normal systemic blood pressure, subjected to treadmill exercise | Attenuated exercise performance, reactivation of myocardial fetal gene expression program (Schuler et al., 2014). |
|          | Adult mice overexpressing the calcitonin receptor-like receptor with baseline hemodynamic variables including normal systemic blood pressure, subjected to treadmill exercise | Enhanced exercise performance (Schuler et al., 2014). |
|          | Adult mice globally deficient for \( \alpha \)CGRP or \( \alpha \)CGRP receptor antagonist-treated WT mice subjected to one-kidney one-clip model of chronic hypertension, subjected to 4 weeks of voluntary wheel running | Impaired survival, reduced voluntary wheel running activity, loss of beneficial effects of exercise on chronic hypertension-induced myocardial fetal gene reprogramming, pathological hypertrophic growth, fibrosis and function (Skaria et al., 2019). |
| Rats     | 6 weeks old rats underwent training protocol for 12 weeks and then treated with \( \alpha \)CGRP receptor antagonist prior subjected to single session endurance training | Attenuation of phospholipase C (PLC/IF3) pathway-mediated adipose tissue lipolysis during exercise (Aveseh et al., 2018). |

\( \alpha \)CGRP may exert hormonal effects (Table 1). An association of endogenous \( \alpha \)CGRP with exercise-induced physiological cardiac hypertrophic growth is yet to be demonstrated in human subjects. However, a recent study has shown that healthy humans exhibiting an increase in circulating \( \alpha \)CGRP concentration also show a higher CRF, carbohydrate oxidation and work performance compared with those showing unaltered plasma \( \alpha \)CGRP concentrations post-exercise, suggesting \( \alpha \)CGRP release may be associated with physiological responses related to exercise (Aracil-Marco et al., 2021; Table 1).

**Cardiovascular Protective Effects of Exercise-Activated \( \alpha \)-Calcitonin Gene-Related Peptide Signaling in Hypertension**

A recent study has shown markedly reduced survival of \( \alpha \)CGRP knock out mice following induction of chronic hypertension. Moreover, it was shown that inhibiting endogenous \( \alpha \)CGRP signaling by gene knock out or treatment with \( \alpha \)CGRP antagonist prior subjected to single session endurance training

out mice with unaltered, baseline systemic BP and calcitonin expression (Lu et al., 1999). Other \( \alpha \)CGRP knock out mice with combined deletion of \( \alpha \)CGRP and calcitonin, and altered baseline cardiovascular variables apparently due to calcitonin deficiency also exhibit impaired survival and cardiac function upon pressure stress (Supowit et al., 2005). Collectively, these findings from mice models suggest that even basal \( \alpha \)CGRP concentration is important for survival and maintaining cardiac function in chronic hypertension, and myocardial protective effects of voluntary exercise in hypertension is mediated by endogenous \( \alpha \)CGRP signaling. Moreover, these findings also suggest that \( \alpha \)CGRP agonism may be a potential alternative or supplemental therapeutic strategy to mimic some of the therapeutically relevant cardioprotective effects of exercise in clinical conditions where patients are mobility impaired or exercise is otherwise contraindicated, i.e., \( \alpha \)CGRP agonists could be used as an exercise mimetic.

Despite several independent previous studies reporting increased plasma \( \alpha \)CGRP concentrations in response to exercise in humans (Schifter et al., 1995; Lind et al., 1996; Hasbak et al., 2003; Aracil-Marco et al., 2021), evidence for a direct effect of increased plasma \( \alpha \)CGRP in mediating cardiovascular benefits of exercise and the molecular pathway(s) involved in these protective effects in humans is still scant and should be the focus of further studies. The intensity of exercise required to increase plasma \( \alpha \)CGRP concentration, and whether there could be a correlation between circulating \( \alpha \)CGRP concentrations with improvements in cardiovascular function in human subjects with chronic hypertension should be addressed.

A recent study employing endogenous \( \alpha \)CGRP inhibition by gene knock out or by the \( \alpha \)CGRP receptor antagonist BIBN4096 BS found that endogenous \( \alpha \)CGRP can protect against elevated BP when nitric oxide synthase is inhibited. Moreover, it was shown that systemic \( \alpha \)CGRP administration can reduce systemic BP and suppress pathological cardiovascular remodeling during states where vascular endothelial/nitric oxide system is dysfunctional. It suggests that \( \alpha \)CGRP agonism may exert protective effects in pathological states associated with
impaired nitric oxide production such as systemic hypertension (Argunhan et al., 2021). αCGRP exerts direct antibacterial action by suppressing myofibroblast differentiation of cardiac fibroblasts through the activation of CAM signaling pathway in the presence of hypertensive peptides such as Angiotensin-II (Skaria et al., 2019). αCGRP's direct effects on inhibiting pathological collagen synthesis in heart fibroblasts (Skaria et al., 2019; Li et al., 2020) is in accordance with BP-independent protective effects of αCGRP in various cell types including cardiomyocytes (Bell et al., 1995; Seur et al., 2005; Schuler et al., 2014).

Efficiency and druggability were the two major issues encountered while translating the previously discovered different, cardioprotective exercise signaling pathways to therapeutic regimen in the clinical setting (Vega et al., 2017). Intravenous administration of αCGRP improves myocardial contractility in patients with congestive HF (Gennari et al., 1990; Shekhar et al., 1991), thereby confirming αCGRP's cardioprotective efficiency in clinical setting. The problem of the short plasma half-life (T1/2) of naïve αCGRP peptide (<6 min) may be circumvented by using a new CGRP-analog (α-Analog) with extended T1/2 (>7 h) (Nilsson et al., 2016). The systemic administration of this acylated α-Analog with improved pharmacokinetics prevented end organ damage, and was well-tolerated in murine model of hypertension and HF (Aubdool et al., 2017).

**Potential Cardiovascular Adverse Effects of Anti-α-Calcitonin Gene-Related Peptide-Based Migraine Prophylaxis**

It is well-established that αCGRP, through vasodilation and regulation of cerebrovascular nociception, plays a critical role in the pathophysiology of migraine (Russell et al., 2014), a highly devastating neurovascular disorder affecting up to 16% of the population worldwide. Therefore, there is unwaning interest in recently approved, αCGRP antagonism-based migraine prophylaxis. The monoclonal antibodies developed against αCGRP or its receptor (with long biological half-life of >45 days) are presumed to have no side effects due to toxic metabolites formation (Vollbracht and Rapoport, 2013; Bigal and Walter, 2014). Several phase-II and phase-III trials conducted to date could not find an increase in cardiovascular adverse effects following treatment with CGRP monoclonal antibodies compared with placebo (Sun et al., 2016; Skljarevski et al., 2018; Ashina et al., 2019; Ferrari et al., 2019; Silberstein et al., 2019; Xu et al., 2019). However, the safety of long-term CGRP antagonist therapy in cardiovascular-compromised patients (e.g., chronic primary hypertension) or those with major cardiovascular risk is not established yet.

A single iv. infusion of the anti-CGRP-receptor monoclonal antibody Erenumab did not affect exercise time in patients with stable angina due to coronary artery disease, prompting the authors to conclude that CGRP receptor blockade may not worsen myocardial ischemia (Depre et al., 2018). However, a serious concern about this study is that it does not provide insights to long-term effects of αCGRP antagonism. Such studies should observe patients for many years after administering antibodies to block αCGRP pathways. To the best of our knowledge, studies observing patients longer than 5 years (Ashina et al., 2019) haven’t been reported yet. Moreover, the study population of Depre et al. (2018) consisted of subjects with stable angina pectoris, often caused by stenosis of the epicardial conducting portions of the coronary artery. Actions of αCGRP are known to be limited in proximal, epicardial parts of the coronary artery bed whereas it is well-known that αCGRP is a potent vasodilator in the intramyocardial, smaller (distal) parts of the coronary artery bed. Another limitation of the study population is that 78% of the subjects were male despite the fact that majority of migraine suffers are females. In female patients with angina pectoris, coronary artery disease is typically diffuse atherosclerosis with coronary microvascular dysfunction but without arteriographically-detectable stenosis. Therefore, it is likely that compared with males, females may respond differently to inhibition of αCGRP signaling. Furthermore, exercise treadmill test was conducted approximately 30 min after intravenous administration of the Erenumab, which may be a too short time period for the large molecular size Erenumab to reach the smooth muscle cells inside the vessels and bind to the CGRP receptor to effectively block it [extensively reviewed by Maassen van den Brink et al. (2018) and Rivera-Mancilla et al. (2020)].

α-calcitonin gene-related peptide deficient mice are resistant to develop diet-induced obesity and exhibit improved glucose handling and insulin sensitivity (Liu et al., 2017) whereas it was shown that treatment with CGRP receptor antagonist olcegepant does not affect systemic glucose and lipid metabolism but impair bone formation in mice model of diet-induced obesity (Köhli et al., 2021). This warrants further investigations on clarifying the role of endogenous CGRP signaling in regulating lipid and glucose metabolism in humans in physiological and pathological conditions and assessing bone status in patients treated with CGRP antagonists.

Strong evidence from preclinical models suggest that αCGRP, through nitric oxide- and vasodilation-dependent and independent mechanisms, protects against hypertension and hypertension-induced end organ damage including HF, and ischemic stroke (Aubdool et al., 2017; Skaria et al., 2019; Mulder et al., 2020). A recent single case study reported the development of a right thalamic infarction following the first dose of Erenumab in a 41-year-old woman with migraine without aura and with a history of long-term use of oral contraceptives (Aradi et al., 2019). As suggested by independent groups across the world, long term inhibition of αCGRP (e.g., for several years in humans) may severely impair cardiovascular function [Maassen van den Brink et al., 2016; Aubdool et al., 2017; Danser and Maassen van den Brink, 2017; extensively reviewed by Rivera-Mancilla et al. (2020)] and may invalidate therapeutically important beneficial cardiac effects of exercise in hypertensive subjects (Skaria et al., 2019).

**CONCLUSION**

Exercise or regular PA undoubtedly reduces the risk of CVD and improves cardiovascular function in individuals with clinically
diagnosed CVD. However, prevalence of PA did not increase considerably over the last decade, and physical inactivity was responsible for more than 800,000 deaths in the year 2019. Moreover, subjects with contraindications for exercise or those with disabilities may fail to meet the PA requirements and thus may not derive the cardiovascular benefits of exercise which necessitates the need for an exercise mimetic. αCGRP could potentially be such an exercise mimetic because findings from preclinical models suggest that activation of endogenous αCGRP signaling may be one of the mechanisms by which exercise improves cardiovascular function in physiological conditions and cardiovascular diseases such as chronic hypertension. On the other hand, αCGRP’s cardiovascular protective effects raise concerns about the potential cardiovascular risks associated with chronic αCGRP antagonism, which has been recently approved by FDA for migraine prophylaxis.

AUTHOR CONTRIBUTIONS

TS and JV designed and wrote the manuscript. Both authors read and approved the final manuscript.

FUNDING

This study received funding from Swiss National Science Foundation (No. 160104) and Novartis Stiftung für Biologisch-Medizinische Forschung (No. 16A012).

REFERENCES

Al-Rubaiee, M., Gangula, P. R., Millis, R. M., Walker, R. K., Umoh, N. A., Cousins, V. M., et al. (2013). Inotropic and lusitropic effects of calcitonin gene-related peptide in the heart. Am. J. Physiol. Heart Circ. Physiol. 304, H1525–H1537. doi: 10.1152/ajpheart.00874.2012

Amini, M., Zayeri, F., and Salehi, M. (2021). Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health 21:401. doi: 10.1186/s12889-021-10429-0

Aracil-Marco, A., Sarabia, J. M., Pastor, D., Guillén, S., López-Grueso, R., Gallar, J., et al. (2021). Acute Increase in Blood αCGRP at Maximal Exercise and Its Association to Cardiorespiratory Fitness, Carbohydrate Oxidation and Work Performed: an Exploratory Study in Young Men. Biology 10:783. doi: 10.3390/biology10080783

Aradi, S., Kaiser, E., and Cuciuciu, B. (2019). Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: a Case Report. J. Stroke Cerebrovasc. Dis. 28:104286. doi: 10.1016/j.jstrokecerebrovasdis.2019.07.002

Argunhan, F., Thapa, D., Aubdool, A. A., Carlini, E., Arkless, K., Hendrikse, E. R., et al. (2021). Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independently of Nitric Oxide In Vivo. Hypertension 77, 1178–1190. doi: 10.1161/hypertensionaha.120.14851

Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Lodick, D., Rippon, G. A., et al. (2019). Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39, 1455–1464. doi: 10.1177/0333102419854082

Aubdool, A. A., Thakore, P., Argunhan, F., Smailie, S. J., Schnelle, M., Srivastava, S., et al. (2017). A Novel alpha-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure. Circulation 136, 367–383. doi: 10.1161/circulationaha.117.023883

Aveshe, M., Koushik-Jahromi, M., Nemat, J., and Esmaeili-Mahani, S. (2018). Serum calcitonin gene-related peptide facilitates adipose tissue lipolysis during exercise via PI3K/PI3K pathways. Endocrine 61, 462–472. doi: 10.1007/s12020-018-1640-2

Bell, D., Schluter, K. D., Zhou, X. J., Mcdermott, B. J., and Piper, H. M. (1995). Hypoerectic effects of calcitonin gene-related peptide (CGRP) and amyllyn on adult mammalian ventricular cardiomyocytes. J. Mol. Cell Cardiol. 27, 2433–2443. doi: 10.1016/j.mcc.1995.0231

Bigal, M. E., and Walter, S. (2014). Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 28, 389–399. doi: 10.1007/s40263-014-0156-4

Cooper, M. A., Kluding, P. M., and Wright, D. E. (2016). Emerging Relationships between Exercise, Sensory Nerves, and Neuropathic Pain. Front. Neurosci. 10, 372. doi: 10.3389/fnins.2016.00372

Danhaier, R. N., Loomes, K. M., Leonard, B. L., Whiting, L., Hay, D. L., Xu, L. Y., et al. (2008). Evidence that alpha-calcitonin gene-related peptide is a neurohormone that controls systemic lipid availability and utilization. Endocrinology 149, 154–160. doi: 10.1210/en.2007-0583

Dansen, A. H. J., and Maassen van den Brink, A. (2017). Calcitonin Gene-Related Peptide Receptor Agonism: a Double-Edged Sword? Circulation 136, 384–387. doi: 10.1161/CIRCULATIONAHA.117.028955

Depre, C., Antalik, L., Starling, A., Koren, M., Eisele, O., Lenz, R. A., et al. (2018). A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache 58, 715–723. doi: 10.1111/head.13316

Ferrari, M. D., Diener, H. C., Ning, X., Galic, M., Cohen, J. M., Yang, R., et al. (2019). Fremanezumab versus placebo for migraine prevention in patients with documented failure to use up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394, 1030–1040. doi: 10.1016/S0140-6736(19)3316

Fiuza-Luces, C., Santos-Lozano, A., Joyner, M., Carrera-Bastos, P., Picazo, O., and Zugaza, J. L. (2018). Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat. Rev. Cardiol. 15, 731–743. doi: 10.1038/s41569-018-0065-1

Gennari, C., Nami, R., Agnusdei, D., and Fischer, J. A. (1990). Improved cardiac function of aortic valve calcified with trilobal platelets. J. Angiol. 11, 108, 89–95. doi: 10.1016/s0140-6736(19)30129-5

Hasbak, P., Lundby, C., Olsen, N. V., Schifter, S., and Knstrup, I. L. (2002). Calcitonin gene-related peptide and adrenomedullin release in humans: effects of exercise and hypoxia. Regul. Pept. 108, 89–95. doi: 10.1016/s0167-0115(02)00129-5

Hasbak, P., Saetrum Opggaard, O., Eskesen, K., Schifter, S., Arendrup, H., Longmore, J., et al. (2003). Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. J. Pharmacol. Exp. Ther. 304, 326–333. doi: 10.1124/jpet.102.037754

Homonko, D. A., and Theriault, E. (1997). Calcitonin gene-related peptide is increased in hindlimb motoneurons after exercise. Int. J. Sports Med. 18, 503–509. doi: 10.1055/s-2007-972672

Kodama, S., Saito, K., Tanaka, S., Maki, M., Yachi, Y., Asumi, M., et al. (2009). Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 301, 2024–2035. doi: 10.1001/jama.2009.681

Koïhl, P., Appelt, J., Otto, E., Jahn, D., Baranowski, A., Bahn, A., et al. (2021). Effects of CGRP receptor antagonism on glucose and bone metabolism in mice with diet-induced obesity. Bone 143, 115646. doi: 10.1016/j.bone.2020.115646

Lechleitner, P., Haring, C., Mair, J., Genser, N., Wiedermann, C. J., Dienstl, F., et al. (1994). Exercise-induced increase in plasma concentrations of calcitonin gene-related peptide in patients with coronary heart disease and healthy controls. Int. J. Angiol. 3, 16–19. doi: 10.1016/bf2014907

Li, W., Zhang, Z., Li, X., Cai, J., Li, D., Du, J., et al. (2020). CGRP derived from cardiac fibroblasts is an endogenous suppressor of cardiac fibrosis. Cardiovasc. Res. 116, 1335–1348. doi: 10.1093/crv/bcz234
Cardiovascular Protection With Exercise-Activated αCGRP

Liang, Y.-L., Khoshouei, M., Deganutti, G., Glukhova, A., Koole, C., Peat, T. S., et al. (2018). Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. *Nature* 561, 492–497. doi: 10.1038/s41586-018-0535-y

Lind, H., Brudin, L., Lindholm, L., and Edvinsson, L. (1996). Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. *Clin. Physiol.* 16, 73–82. doi: 10.1111/j.1470-978x.1996.00057.x

Liu, T., Kamiyoshi, A., Sakurai, T., Ichikawa-Shindo, Y., Kawate, H., Yang, L., et al. (2017). Endogenous Calcitonin Gene-Related Peptide Regulates Lipid Metabolism and Energy Homeostasis in Male Mice. *Endocrinology* 158, 1194–1206. doi: 10.1210/endo.2016-1510

Lu, J. T., Son, Y. J., Lee, J., Jetton, T. L., Shiota, M., Moscoso, L., et al. (1999). Mice lacking alpha-calcitonin-gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. *Mol. Cell. Neurosci.* 14, 99–120. doi: 10.1006/mcne.1999.0767

Maassen van den Brink, A., Rubio-Beltrán, E., Duncker, D., and Villalón, C. M. (2018). Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed. *Headache*. *J. Head Face Pain* 58, 1257–1258.

Maassen van den Brink, A., Meijer, J., Villalon, C. M., and Ferrari, M. D. (2016). Wiping Out CGRP: potential Cardiovascular Risks. *Trends Pharmacol. Sci.* 37, 779–788. doi: 10.1016/j.tips.2016.06.002

Mulder, I. A., Li, M., De Vries, T., Qin, Y., Nagayaswa, T., Sugimoto, K., et al. (2020). Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. *Ann. Neurol.* 88, 771–784. doi: 10.1002/ana.25381

Mulderry, P. K., Ghatki, M. A., Spokks, R. A., et al. (1998). Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. *Neuroscience* 25, 195–205. doi: 10.1016/j.snb.1997.08.018

Nakanishi, M., Hata, K., Nagayama, T., Sakurai, T., Nishisho, T., Wakabayashi, H., et al. (2010). Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK- CREB cascade: a potential mechanism of inflammatory pain. *Mol. Biol. Cell* 21, 2568–2577. doi: 10.1091/mbc.E10–01–0049

Nilsson, C., Hansen, T. K., Rosenquist, J., Hartmann, B., Kodra, J. T., Lau, J. F., et al. (2016). Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. *Eur. J. Pharmacol.* 773, 24–31. doi: 10.1016/j.ejphar.2016.01.003

Parnow, A., Gharaikanlou, R., Gorginkaraji, Z., Rajabi, S., Esfami, R., Hedaya, M., et al. (2012). Effects of endurance and resistance training on calcitonin gene-related peptide and acetylcholine receptor at slow and fast twitch skeletal muscles and sciatic nerve in male wistar rats. *Int. J. Pept.* 2012:962651. doi: 10.1155/2012/962651

Pinckard, K., Baskin, K. K., and Stanford, K. I. (2019). Effects of Exercise to Improve Cardiovascular Health. *Front. Cardiovasc. Med.* 6:68. doi: 10.3389/fcvm.2019.00069

Rivera-Mancilla, E., Villalón, C. M., and Maassenvandenbrink, A. (2020). CGRP inhibitors for migraine prophylaxis: a safety review. *Expert Opin. Drug Saf.* 19, 1237–1250. doi: 10.1080/14740338.2020.1811229

Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Tassone, F. M., and Ferrari, M. D. (2016). Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol.* 15, 382–390. doi: 10.1016/S1474-4422(16)00019-3

Supowit, S. C., Rao, A., Bowers, M. C., Zhao, H., Fink, G., Steffeck, B., et al. (2005). Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. *Hypertension* 45, 109–114. doi: 10.1161/01.HYP.0000151130.34874.f4

Tarperi, C., Sanchis-Gomar, F., Montagnana, M., Danese, G. L., Belati, E., et al. (2020). Effects of endurance exercise on serum concentration of calcitonin gene-related peptide (CGRP): a potential link between exercise intensity and headache. *Clin. Chem. Lab. Med.* 58, 1707–1712. doi: 10.1515/cclm-2019-1337

Vega, R. B., Konhilas, J. P., Kelly, D. P., and Leinwand, L. A. (2017). Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. *Cell Metab.* 25, 1012–1026. doi: 10.1016/j.cmet.2017.04.025

Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., and Callaway, C. W. (2021). Heart Disease and Stroke Statistics &#x28;2021&#x29;. *Circulation* 143, e254–e743.

Vollbracht, S., and Rapoport, A. M. (2013). The pipeline in headache therapy. *CNS Drugs* 27, 717–729. doi: 10.1007/s40263-013-0090-x

Wang, X., and Fiscus, R. R. (1997). Lactic acid potentiates bradykinin- and low-pH-induced release of CGRP from rat spinal cord slices. *Am. J. Physiol.* 273, C92–C98. doi: 10.1152/ajpcell.1997.273.1.C92

Xu, D., Chen, D., Zhu, L. N., Tan, G., Wang, H. J., Zhang, Y., et al. (2019). Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. *Cephalalgia* 39, 863–911. doi: 10.1177/0333102418828907

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Skaria and Vogel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.